Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GRI
stocks logo

GRI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast GRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRI is 22.50 USD with a low forecast of 10.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast GRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRI is 22.50 USD with a low forecast of 10.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.140
sliders
Low
10.00
Averages
22.50
High
35.00
Current: 2.140
sliders
Low
10.00
Averages
22.50
High
35.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$10
2025-04-14
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$10
2025-04-14
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Initiates
$10
2024-12-09
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$10
2024-12-09
Initiates
Strong Buy
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$12 → $13
2024-12-05
Reason
Ascendiant Capital
Edward Woo
Price Target
$12 → $13
2024-12-05
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for GRI Bio Inc (GRI.O) is -0.57, compared to its 5-year average forward P/E of -0.20. For a more detailed relative valuation and DCF analysis to assess GRI Bio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.20
Current PE
-0.57
Overvalued PE
0.05
Undervalued PE
-0.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.14
Undervalued EV/EBITDA
-0.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GRI News & Events

Events Timeline

(ET)
2025-09-11
08:47:45
GRI Bio Releases Six-Week Lung Function Results from Phase 2a Trial of GRI-0621
select
2025-07-01 (ET)
2025-07-01
08:47:39
GRI Bio completes enrollment in Phase 2a study of GRI-0621
select
2025-06-26 (ET)
2025-06-26
08:03:49
GRI Bio reports 6-week interim safety data from Phase 2a study of GRI-0621
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
09-22Benzinga
Ascendiant Capital Reaffirms Buy Rating on GRI Bio, Increases Price Target to $35

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects traders with over 10,000 members and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
2.0
09-12Benzinga
Adobe Shares Rise Over 4%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Adobe's Strong Performance: Adobe Inc. shares rose 4.4% in pre-market trading after reporting better-than-expected Q3 earnings of $5.31 per share and revenue of $5.99 billion, along with an improved fiscal 2025 outlook.

  • Notable Gainers: Several stocks saw significant pre-market gains, including HCW Biologics (up 94.3%), Huize Holding (up 61.5%), and Millennium Group (up 46.2%), following positive announcements and financial results.

  • Major Losers: Next Technology Holding experienced a sharp decline of 50.6% due to a reverse stock split, while Rent the Runway fell 27.1% after disappointing Q2 earnings.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with notable movements in both directions following recent earnings reports and company announcements.

[object Object]
Preview
9.0
09-11Newsfilter
GRI Bio Releases 6-Week Interim Lung Function Results from Ongoing Phase 2a Study on Idiopathic Pulmonary Fibrosis (IPF)

  • Interim Study Results: The Phase 2a study of GRI-0621 for treating Idiopathic Pulmonary Fibrosis (IPF) shows no decline in lung function after 6 weeks, with positive serum biomarker data suggesting an anti-fibrotic effect.

  • Safety and Future Expectations: GRI-0621 has been deemed safe and well-tolerated, with topline data expected in Q3 2025, as the study continues to assess its efficacy and safety in a randomized, placebo-controlled design.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is GRI Bio Inc (GRI) stock price today?

The current price of GRI is 2.14 USD — it has increased 8.08 % in the last trading day.

arrow icon

What is GRI Bio Inc (GRI)'s business?

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).

arrow icon

What is the price predicton of GRI Stock?

Wall Street analysts forecast GRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRI is 22.50 USD with a low forecast of 10.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is GRI Bio Inc (GRI)'s revenue for the last quarter?

GRI Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is GRI Bio Inc (GRI)'s earnings per share (EPS) for the last quarter?

GRI Bio Inc. EPS for the last quarter amounts to -1.28 USD, decreased -88.79 % YoY.

arrow icon

What changes have occurred in the market's expectations for GRI Bio Inc (GRI)'s fundamentals?

The market is revising No Change the revenue expectations for GRI Bio, Inc. (GRI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 28.92%.
arrow icon

How many employees does GRI Bio Inc (GRI). have?

GRI Bio Inc (GRI) has 3 emplpoyees as of December 05 2025.

arrow icon

What is GRI Bio Inc (GRI) market cap?

Today GRI has the market capitalization of 6.94M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free